Van Naarden Jacob 4

What Happened
Jacob Van Naarden, EVP and President of LLY Oncology & Head Corporate BD at Eli Lilly, received an award/grant of 4,865.888 shares on February 9, 2026. The grant was reported at a per-share value of $1,044.67, for a total reported value of $5,083,247. This was an award (code A), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-09; filing date: 2026-02-11 (appears timely).
• Grant: 4,865.888 shares at $1,044.67 per share; total reported value $5,083,247.
• Shares owned after transaction: not specified in this Form 4.
• Footnote F1: Reporting person disclaims beneficial ownership except to extent of pecuniary interest.
• Footnote F2: On Feb 5, 2026 the reporting person’s spouse transferred 5,302 shares into a spousal lifetime access trust (the reporting person is trustee and beneficiary); the transfer included 1,000 spouse‑held shares previously reported as directly held due to an administrative error.

Context
Grants/awards are typically compensation-related and do not necessarily indicate a new personal purchase or sale decision. The footnote about the spousal trust and the disclaimer of beneficial ownership are administrative details that affect reported holdings but do not change the fact this filing records a compensation award.